| Name | Title | Contact Details |
|---|
Your partner for nuclear medicine and molecular imaging solutions.
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
HI Bio is a clinical stage biotechnology company focused on the development of targeted therapies for patients with immune mediated diseases (IMDs).
Stayma Consulting Services is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Peer Direct is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.